Niagen Bioscience, Inc. Common Stock NAGE Business Segments
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $423K-47.8% | $772K-1.5% | $799K+1.0% | $811K+13.6% | $784K+16.8% | |
| Consumer Products segment | $22.41M+4.2% | $26.02M+43.6% | $22.7M+21.7% | $21.5M+23.9% | $18.12M+4.2% | |
| Corporate and other | $74K— | —— | —— | —— | —— | |
| Ingredients segment | $8.56M+4.8% | $7.2M+7.9% | $7.62M+131% | $8.17M+99.8% | $6.67M+369% | |
| Pharmaceuticals segment | $0— | —— | —— | $0— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Niagen Bioscience, Inc. Common Stock break its business down?
- Niagen Bioscience, Inc. Common Stock (NAGE) reports net sales by business across 5 parts — Analytical Reference Standards and Services segment, Consumer Products segment, Corporate and other, Ingredients segment and Pharmaceuticals segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Niagen Bioscience, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Niagen Bioscience, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
